Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
JAMA Cardiology shared a post on LinkedIn about a recent article by Giuseppe Biondi-Zoccai et al., adding:
“Editorial: A network meta-analysis of randomized clinical trials comparing clopidogrel, prasugrel, and ticagrelor in patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI) indicates that prasugrel offers the most favorable efficacy-safety profile for reducing major adverse cardiovascular events, myocardial infarction, and stent thrombosis.
Clinicians are advised that selection of a P2Y12 inhibitor should be individualized to account for patient comorbidities, bleeding risk, and concurrent therapies, with clopidogrel and ticagrelor remaining appropriate alternatives for specific scenarios.”
Title: Prasugrel – The Default P2Y12 Inhibitor After PCI for ACS?
Authors: Giuseppe Biondi-Zoccai, Salvatore Giordano, Nicola Corcione
Stay updated with Hemostasis Today.
-
Aug 19, 2026, 09:12Charlie Berman: Infections Following Mechanical Thrombectomy for Acute Stroke
-
Aug 19, 2026, 08:05Charles Cohen: Why Women Wait Years Longer for a Bleeding Disorder Diagnosis
-
Aug 19, 2026, 07:42Chukwuemeka Amarachi: Thalassemia – Types, Diagnosis and Management
-
Aug 19, 2026, 07:15Ajay Kumar: Real-World Outcomes of Plasma Exchange in NMOSD
-
Aug 19, 2026, 07:02Amer Zeidan: Managing Anemia in Lower-Risk MDS
-
Aug 19, 2026, 06:24GT Connect – Connecting the GT Community – Glanzmann’s Research Foundation
-
Aug 19, 2026, 01:43Elvira Grandone: Cancer and Thrombosis in Women – Where Do We Stand?
-
Aug 19, 2026, 01:37Ifeanyichukwu Ifechidere: Coagulation Knowledge – A Core Skill in Internal Medicine
-
Aug 19, 2026, 01:34Tommy Alfaro Moya: Celebrating a New Chapter Contribution in Clinical Hematology and Hemato-Oncology